Briggs Morrison - 02 Feb 2022 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role: President, Head of R&D, Director
Signature: /s/ Michael A. Metzger, Attorney-in-fact
Issuer symbol: SNDX
Transactions as of: 02 Feb 2022
Net transactions value: +$2,526,400
Form type: 4
Filing time: 03 Feb 2022, 16:32:43 UTC
Previous filing: 19 Jan 2022
Next filing: 13 Apr 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SNDX	Stock Options (Right to buy)	Award	$2,526,400	+160,000		$15.79	160,000	02 Feb 2022	Common Stock	160,000	$15.79	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The securities awarded on 02/02/2022 were in the form of stock options issued pursuant to the Syndax Pharmaceuticals, Inc. 2015 Omnibus Incentive Plan. Options to purchase 100,000 shares of common stock shall vest in 48 successive equal monthly installments measured from 02/02/2022. Options to purchase 60,000 shares of common stock shall vest periodically upon the Issuer achieving certain milestones.

Content

The securities awarded on 02/02/2022 were in the form of stock options issued pursuant to the Syndax Pharmaceuticals, Inc. 2015 Omnibus Incentive Plan. Options to purchase 100,000 shares of common stock shall vest in 48 successive equal monthly installments measured from 02/02/2022. Options to purchase 60,000 shares of common stock shall vest periodically upon the Issuer achieving certain milestones.